Comparative Pharmacology
Head-to-head clinical analysis: BLENOXANE versus MITOSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLENOXANE versus MITOSOL.
BLENOXANE vs MITOSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bleomycin acts by binding to DNA and inducing single- and double-strand breaks via free radical formation, requiring metal ions (Fe2+, Cu+) and oxygen. It inhibits DNA, RNA, and protein synthesis, with cell cycle phase specificity (G2 and M phases).
Mitomycin C is an alkylating antibiotic that inhibits DNA synthesis by forming cross-links between complementary DNA strands, thereby blocking DNA replication and transcription.
Blenoxane is administered as 0.25–0.5 units/kg (10–20 units/m²) intravenously, intramuscularly, or subcutaneously once weekly or twice weekly. Typical adult dose: 15–30 units weekly.
0.04 mg/kg intravenously once weekly for 4 weeks, then every 3 weeks thereafter; maximum single dose 3.5 mg.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours (biphasic: initial 0.5-1 hr, terminal 2-3 hr); prolonged to ~10-20 hours in severe renal impairment (CrCl <30 mL/min)
Terminal: 3-6 hours; in renal impairment, extends to 10-20 hours
Renal (60-70% as active drug); remainder primarily hepatic metabolism with biliary excretion of metabolites
Renal: 60% unchanged; biliary/fecal: 40% as metabolites
Category C
Category C
Antineoplastic Antibiotic
Antineoplastic Antibiotic